Information Provided By:
Fly News Breaks for March 15, 2016
IMMU
Mar 15, 2016 | 07:45 EDT
After Immunomedics late yesterday announced that it's terminating its Phase 3 PANCRIT-1 trial, Wells Fargo says that this development was expected, given the trial's high clinical hurdle and invalidated target. Wells cut its price target on the stock to $3-$3.50 from $4-$4.50 in response to the news. However, the firm continues to believe that the company can find a partner for its IMMU132 drug, and it keeps an Outperform rating on the shares.
News For IMMU From the Last 2 Days
There are no results for your query IMMU